当地时间3月26日，诺和诺德在年度股东大会上宣布任命美国糖果巨头玛氏（Mars）公司首席执行官 波尔·魏拉赫（Poul Weihrauch）为董事会观察员。诺和诺德表示，减重药市场正越来越受消费者驱 动，公司正在研究消费者行为。 编辑 ｜ 钉钉 记者｜钱童心 ...

Companies Novo Nordisk A/S Reporting by Carlos Méndez in Mexico City; Editing by Rashmi Aich Our Standards: The Thomson Reuters Trust Principles., opens new tab US FDA approves Novo's insulin injection for type 2 diabetes | Reuters Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv The logo of Danish drugmaker Novo Nordisk, Copenhagen, Denmark, September 26, 2023. REUTERS/Tom Little REFILE - CORRECTING LOCATION Purchase Licensing Rights, opens new tab Follow March ...

Awiqli® (insulin icodec-abae) injection is the first-ever once-weekly basal insulin approved by the FDAAwiqli® offers adults with type 2 diabetes an alternative to daily basal insulin injections, reducing these injections from seven to one per weekNovo Nordisk expects to launch Awiqli® nationwide in the US in the second half of 2026. Bagsværd, Denmark, 27 March 2026 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL ...

整理 | GLP1减重宝典内容团队 3月25日，联邦制药与诺和诺德共同宣布，GLP-1/GIP/GCG三靶点受体激动剂UBT251在中国2型糖尿病患者中的II期临床研究取得主要终点成 功。对当下竞争激烈的代谢病赛道来说，这不只是又一项积极数据，而是一组足以引发市场重新定价的结果：在24周治疗后，UBT251最高剂 量组糖化血红蛋白降幅达到2.16%，优于司美格鲁肽1mg组的1.77%；体重降幅最高达到9.8%，也明显高于司美格鲁肽1mg组的4.8%。在减重药 和降糖药加速融合的时代，这样的数据已经不是简单的跟跑，而是一次带有挑战意味的正面逼近。 ▍真正值得关注的，不只是赢了司美格鲁肽，而是赢得很全面 从这项研究披露的核心结果看，UBT251的亮点并不局限于单一指标。211名中国2型糖尿病患者被随机分配接受每周一次2mg、4mg、6mg剂量 的UBT251，或安慰剂，或司美格鲁肽1mg治疗24周。患者基线平均HbA1c为8.12%，平均体重80.1kg，平均BMI为29.1kg/m²。在这样的基线条 件下，UBT251不仅在降糖上拉开了与安慰剂和司美格鲁肽的差距，在减重方面也体现出更强的代谢干预能力。更进一步的 ...

Follow Mars Inc Novo Nordisk appoints Mars CEO as board observer | Reuters Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, February 4, 2026. REUTERS/Tom Little/File Photo Purchase Licensing Rights, opens new tab Companies H & M Hennes & Mauritz AB Follow Sign up here. Novo Nordisk A/S Follow The company is leaning into telehealth, retail part ...

礼来逐步退出胰岛素市场，利好国产胰岛素企业 20260325 摘要 礼来计划 2027Q2 前退出欧洲及亚非拉胰岛素市场，仅保留出厂价维持 20 美元以上的高盈利美国市场。 诺和诺德与礼来战略重心转向 GLP-1 及四代胰岛素，通过提价或减产主 动收缩二、三代胰岛素全球供应。 礼来退出将释放欧美以外约 13.5 亿美元市场空间，中国三家企业预计 承接约 7 亿美元规模及 3 亿美元净利增量。 亚非拉等新兴市场胰岛素需求增速达 15%，远高于国内 5%，中国企业 凭借全产业链成本优势实现"中国替代"。 全球胰岛素供应高度集中，除跨国三巨头外，仅中、俄、印、伊少数企 业具备规模化原料药及制剂产能。 未来格局分层：中国企业主导全球二、三代胰岛素存量市场，跨国药企 聚焦四代胰岛素及 GLP-1 等高利润创新药。 Q&A 礼来（Eli Lilly）近期宣布将逐步退出欧洲胰岛素市场，这一决策的背景是什 么？诺和诺德（Novo Nordisk）在此方面有无类似动向？ 礼来逐步退出胰岛素市场的决策并非突然，其根本原因在于 GLP-1 药物的高盈 利性，相较之下，胰岛素业务利润空间有限。将胰岛素的发酵产能转向生产 GLP-1， ...

Novo Nordisk A/S (NYSE:NVO) is one of the best undervalued stocks under $50 to invest in now. Bernstein initiated coverage of Novo Nordisk A/S (NYSE:NVO) with an Underperform rating and $175 price target on March 18. The firm told investors in a research note that the company’s earnings downgrade cycle is not over, adding that it believes Novo Nordisk’s (NYSE:NVO) catalyst path “looks bare.” It also said that the company’s weight loss drugs will underperform in the United States on lower volume share and m ...

Key Takeaways Novo Nordisk and its partner reported phase II data for UBT251 in Chinese patients with type II diabetes.UBT251 showed up to a 2.16% HbA1c reduction and 9.8% weight loss, outperforming semaglutide and placebo.Novo Nordisk plans a global phase II in 2026, while its partner prepares for phase III trials in China.Novo Nordisk (NVO) and its partner, The United Laboratories International Holdings Limited ("TUL"), jointly announced top-line data from a phase II study in China, evaluating UBT251, a n ...

Novo Nordisk cuts Wegovy price in South Africa for a second time | Reuters Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv Boxes of Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. REUTERS/Hollie Adams Purchase Licensing Rights, opens new tab JOHANNESBURG, March 25 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tabis cutting South African prices of its weight-loss drug Wegovy for a second time since it la ...

The United Laboratories International Holdings Ltd. (TUL) and Novo Nordisk A/S (NVO) have announced promising topline results from a phase 2 trial of investigational drug UBT251 in Chinese patients with type 2 diabetes.UBT251 is a triple agonist targeting the GLP-1, GIP, and glucagon receptors (triple G) and is being co-developed by United Biotechnology, a subsidiary of United Labs, and Novo Nordisk. Triple G agonists are designed to treat type 2 diabetes and obesity. In the phase 2 trial, conducted by Uni ...